advanced-chemistry-2019-keynote

3 / 4

2nd European Congress on Advanced Chemistry
May 09-10, 2019 | Stockholm, Sweden
Page 21 Journal of Organic & Inorganic Chemistry
ISSN: 2472-1123 Advanced Chemistry 2019
Introduction: WISP-1 (Wnt1 inducible signaling pathway protein--1) is a relatively
new adipokine, associated with insulin resistance. The aim of the study was to
compare the levels of WISP-1 in women with type 2 diabetes and healthy controls
and determine its association with metabolic parameters and with markers of
endothelial dysfunction.
Methods: 50 women with type 2 diabetes and 35 healthy women were included
in the study. In addition to the WISP-1, levels of adiponectin, adipocyte-fatty
acid binding protein (A-FABP), anthropometric and lipid parameters, markers
of inflammation, insulin resistance and glucose control were assessed in all
participants. Von Willebrand factor (vWF) and tissue plasminogen activator (t-PA)
served as the indicators of endothelial damage.
Results: Compared to healthy controls women with type 2 diabetes had
higher levels of WISP-1 [54(33-84) pg/ml versus 35(29-61) pg/ml; p<0.05],
which significantly correlated positively with hs-C-reactive protein (hs-CRP)
(ρ=0.22), C-peptide (ρ=0.23), t-PA (ρ=0.24), A-FABP (ρ=0.30) and negatively
with adiponectin (ρ=-0.27). In multivariate regression analysis hs-CRP was only
independent predictor for WISP-1 levels.
Conclusion: Women with type 2 diabetes had significantly higher levels of WISP-1
that were associated with inflammation, insulin resistance and other adipokines.
WISP-1 correlation with t-PA showed that, this adipokine could play a role in the
vascular damage, maybe through its proinflammatory effect.
Wnt1-inducible signaling pathway
protein-1 in women with type
2 diabetes, its relationship to
parameters of chronic inflammation
and endothelial dysfunction
David Karasek
University Hospital Olomouc, Czech Republic
Biography
David Karasek has completed his MD and PhD from
Medical Faculty of Palacky University Olomouc
(Czech Republic). He is the Deputy Head of the 3rd
Department of Internal Medicine–nephrology, rheu-
matology and endocrinology and the Head of Center
for Diabetes of University Hospital Olomouc. He has
published more than 120 papers in reputed journals
(as the first author of 44 papers) and has been serv-
ing as an Editorial Board Member of four scientific
journals (Interní medicína pro praxi, Farmakoterapeu-
tická revue, Hypertenze a kardiovaskulární prevence,
Journal of Disease Markers) .
David Karasek, J Org Inorg Chem 2019, Volume:5
DOI: 10.21767/2472-1123-C2-022